Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

PTPI vs PRGO vs CVS vs MCK vs CAH

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
PTPI
Petros Pharmaceuticals, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$56K
5Y Perf.-100.0%
PRGO
Perrigo Company plc

Drug Manufacturers - Specialty & Generic

HealthcareNYSE • IE
Market Cap$1.62B
5Y Perf.-73.8%
CVS
CVS Health Corporation

Medical - Healthcare Plans

HealthcareNYSE • US
Market Cap$115.54B
5Y Perf.+32.6%
MCK
McKesson Corporation

Medical - Distribution

HealthcareNYSE • US
Market Cap$90.21B
5Y Perf.+323.5%
CAH
Cardinal Health, Inc.

Medical - Distribution

HealthcareNYSE • US
Market Cap$43.22B
5Y Perf.+242.9%

PTPI vs PRGO vs CVS vs MCK vs CAH — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
PTPI logoPTPI
PRGO logoPRGO
CVS logoCVS
MCK logoMCK
CAH logoCAH
IndustryDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & GenericMedical - Healthcare PlansMedical - DistributionMedical - Distribution
Market Cap$56K$1.62B$115.54B$90.21B$43.22B
Revenue (TTM)$725K$4.18B$407.90B$403.43B$250.55B
Net Income (TTM)$-7M$-1.82B$2.93B$4.76B$1.56B
Gross Margin63.5%34.2%13.9%3.6%3.7%
Operating Margin-18.4%-4.1%1.5%1.5%0.9%
Forward P/E5.5x12.4x16.7x17.1x
Total Debt$7M$3.97B$93.59B$8.61B$9.35B
Cash & Equiv.$4M$532M$8.51B$3.98B$3.87B

PTPI vs PRGO vs CVS vs MCK vs CAHLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

PTPI
PRGO
CVS
MCK
CAH
StockDec 20May 26Return
Petros Pharmaceutic… (PTPI)1000.0-100.0%
Perrigo Company plc (PRGO)10026.2-73.8%
CVS Health Corporat… (CVS)100132.6+32.6%
McKesson Corporation (MCK)100423.5+323.5%
Cardinal Health, In… (CAH)100342.9+242.9%

Price return only. Dividends and distributions are not included.

Quick Verdict: PTPI vs PRGO vs CVS vs MCK vs CAH

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MCK leads in 3 of 7 categories (5-stock set), making it the strongest pick for growth and revenue expansion and profitability and margin quality. Petros Pharmaceuticals, Inc. is the stronger pick specifically for dividend income and shareholder returns. PRGO, CVS, and CAH also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
PTPI
Petros Pharmaceuticals, Inc.
The Income Pick

PTPI is the #2 pick in this set and the best alternative if dividends is your priority.

  • 100.0% yield, 1-year raise streak, vs CAH's 1.1%
Best for: dividends
PRGO
Perrigo Company plc
The Defensive Pick

PRGO ranks third and is worth considering specifically for defensive.

  • Beta 1.21, yield 9.8%, current ratio 2.76x
  • Lower P/E (5.5x vs 17.1x)
Best for: defensive
CVS
CVS Health Corporation
The Insurance Pick

CVS is the clearest fit if your priority is momentum.

  • +37.4% vs PTPI's -94.4%
Best for: momentum
MCK
McKesson Corporation
The Growth Play

MCK carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth 12.4%, EPS growth 49.2%, 3Y rev CAGR 13.4%
  • 339.0% 10Y total return vs CAH's 158.8%
  • 12.4% revenue growth vs PTPI's -12.2%
  • 1.2% margin vs PTPI's -9.7%
Best for: growth exposure and long-term compounding
CAH
Cardinal Health, Inc.
The Income Pick

CAH is the clearest fit if your priority is income & stability and sleep-well-at-night.

  • Dividend streak 20 yrs, beta 0.01, yield 1.1%
  • Lower volatility, beta 0.01, current ratio 0.94x
  • Beta 0.01 vs PTPI's 1.45
Best for: income & stability and sleep-well-at-night
See the full category breakdown
CategoryWinnerWhy
GrowthMCK logoMCK12.4% revenue growth vs PTPI's -12.2%
ValuePRGO logoPRGOLower P/E (5.5x vs 17.1x)
Quality / MarginsMCK logoMCK1.2% margin vs PTPI's -9.7%
Stability / SafetyCAH logoCAHBeta 0.01 vs PTPI's 1.45
DividendsPTPI logoPTPI100.0% yield, 1-year raise streak, vs CAH's 1.1%
Momentum (1Y)CVS logoCVS+37.4% vs PTPI's -94.4%
Efficiency (ROA)MCK logoMCK5.7% ROA vs PTPI's -114.5%, ROIC 74.5% vs -7.3%

PTPI vs PRGO vs CVS vs MCK vs CAH — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

PTPIPetros Pharmaceuticals, Inc.
FY 2024
Medical Devices
100.0%$3M
PRGOPerrigo Company plc
FY 2025
Consumer Self-Care Americas
60.8%$2.6B
Consumer Self-Care International
39.2%$1.7B
CVSCVS Health Corporation
FY 2025
Pharmacy Revenue
58.9%$229.0B
Premiums
34.6%$134.8B
Front Store Revenue
5.5%$21.5B
Product and Service, Other
1.0%$3.9B
MCKMcKesson Corporation
FY 2026
North American Pharmaceutical Segment
83.4%$336.7B
Oncology And Multispecialty Segment
12.0%$48.4B
Medical-Surgical Solutions Segment
2.9%$11.5B
Prescription Technology Solutions Segment
1.4%$5.8B
Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment
0.3%$1.0B
CAHCardinal Health, Inc.
FY 2025
Pharmaceutical Member
91.9%$204.6B
GMPD
5.7%$12.6B
Other Operating Segment
2.4%$5.4B

PTPI vs PRGO vs CVS vs MCK vs CAH — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLPRGOLAGGINGCAH

Income & Cash Flow (Last 12 Months)

Evenly matched — PTPI and MCK each lead in 2 of 6 comparable metrics.

CVS is the larger business by revenue, generating $407.9B annually — 562315.0x PTPI's $725,403. MCK is the more profitable business, keeping 1.2% of every revenue dollar as net income compared to PTPI's -9.7%. On growth, CAH holds the edge at +11.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricPTPI logoPTPIPetros Pharmaceut…PRGO logoPRGOPerrigo Company p…CVS logoCVSCVS Health Corpor…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …
RevenueTrailing 12 months$725,403$4.2B$407.9B$403.4B$250.5B
EBITDAEarnings before interest/tax-$12M$58M$10.5B$6.8B$3.2B
Net IncomeAfter-tax profit-$7M-$1.8B$2.9B$4.8B$1.6B
Free Cash FlowCash after capex-$5M$108M$7.4B$6.0B$4.4B
Gross MarginGross profit ÷ Revenue+63.5%+34.2%+13.9%+3.6%+3.7%
Operating MarginEBIT ÷ Revenue-18.4%-4.1%+1.5%+1.5%+0.9%
Net MarginNet income ÷ Revenue-9.7%-43.5%+0.7%+1.2%+0.6%
FCF MarginFCF ÷ Revenue-6.7%+2.6%+1.8%+1.5%+1.8%
Rev. Growth (YoY)Latest quarter vs prior year-100.0%-7.2%+6.2%+6.0%+11.0%
EPS Growth (YoY)Latest quarter vs prior year+95.9%-56.4%+63.1%+37.0%-19.5%
Evenly matched — PTPI and MCK each lead in 2 of 6 comparable metrics.

Valuation Metrics

PRGO leads this category, winning 5 of 6 comparable metrics.

At 19.2x trailing earnings, MCK trades at a 71% valuation discount to CVS's 65.1x P/E. On an enterprise value basis, PRGO's 7.4x EV/EBITDA is more attractive than CAH's 15.9x.

MetricPTPI logoPTPIPetros Pharmaceut…PRGO logoPRGOPerrigo Company p…CVS logoCVSCVS Health Corpor…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …
Market CapShares × price$56,182$1.6B$115.5B$90.2B$43.2B
Enterprise ValueMkt cap + debt − cash$4M$5.1B$200.6B$94.9B$48.7B
Trailing P/EPrice ÷ TTM EPS-0.00x-1.14x65.14x19.19x28.47x
Forward P/EPrice ÷ next-FY EPS est.5.53x12.39x16.66x17.09x
PEG RatioP/E ÷ EPS growth rate0.43x
EV / EBITDAEnterprise value multiple7.43x13.38x15.27x15.88x
Price / SalesMarket cap ÷ Revenue0.01x0.38x0.29x0.22x0.19x
Price / BookPrice ÷ Book value/share0.55x1.53x11.63x
Price / FCFMarket cap ÷ FCF11.17x14.80x14.66x23.36x
PRGO leads this category, winning 5 of 6 comparable metrics.

Profitability & Efficiency

MCK leads this category, winning 6 of 9 comparable metrics.

MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $-2 for PTPI. MCK carries lower financial leverage with a 1.10x debt-to-equity ratio, signaling a more conservative balance sheet compared to PRGO's 1.35x. On the Piotroski fundamental quality scale (0–9), MCK scores 7/9 vs PTPI's 3/9, reflecting strong financial health.

MetricPTPI logoPTPIPetros Pharmaceut…PRGO logoPRGOPerrigo Company p…CVS logoCVSCVS Health Corpor…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …
ROE (TTM)Return on equity-2.1%-50.7%+3.9%+3.0%
ROA (TTM)Return on assets-114.5%-19.8%+1.1%+5.7%+2.8%
ROICReturn on invested capital-7.3%+3.7%+5.0%+74.5%+33.8%
ROCEReturn on capital employed-2.3%+4.3%+6.1%+43.1%+19.2%
Piotroski ScoreFundamental quality 0–934576
Debt / EquityFinancial leverage1.35x1.24x1.10x
Net DebtTotal debt minus cash$4M$3.4B$85.1B$4.6B$5.5B
Cash & Equiv.Liquid assets$4M$532M$8.5B$4.0B$3.9B
Total DebtShort + long-term debt$7M$4.0B$93.6B$8.6B$9.3B
Interest CoverageEBIT ÷ Interest expense-79.35x-7.20x2.11x33.79x6.38x
MCK leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — CVS and MCK and CAH each lead in 2 of 6 comparable metrics.

A $10,000 investment in MCK five years ago would be worth $37,043 today (with dividends reinvested), compared to $0 for PTPI. Over the past 12 months, CVS leads with a +37.4% total return vs PTPI's -94.4%. The 3-year compound annual growth rate (CAGR) favors CAH at 31.1% vs PTPI's -95.9% — a key indicator of consistent wealth creation.

MetricPTPI logoPTPIPetros Pharmaceut…PRGO logoPRGOPerrigo Company p…CVS logoCVSCVS Health Corpor…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …
YTD ReturnYear-to-date-12.5%-13.6%+14.7%-10.5%-10.2%
1-Year ReturnPast 12 months-94.4%-52.0%+37.4%+7.2%+26.1%
3-Year ReturnCumulative with dividends-100.0%-58.1%+41.2%+102.1%+125.5%
5-Year ReturnCumulative with dividends-100.0%-60.3%+19.8%+270.4%+232.0%
10-Year ReturnCumulative with dividends-100.0%-77.7%+6.6%+339.0%+158.8%
CAGR (3Y)Annualised 3-year return-95.9%-25.2%+12.2%+26.4%+31.1%
Evenly matched — CVS and MCK and CAH each lead in 2 of 6 comparable metrics.

Risk & Volatility

Evenly matched — CVS and MCK each lead in 1 of 2 comparable metrics.

MCK is the less volatile stock with a -0.02 beta — it tends to amplify market swings less than PTPI's 1.45 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CVS currently trades 99.6% from its 52-week high vs PTPI's 3.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricPTPI logoPTPIPetros Pharmaceut…PRGO logoPRGOPerrigo Company p…CVS logoCVSCVS Health Corpor…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …
Beta (5Y)Sensitivity to S&P 5001.45x1.21x0.13x-0.02x0.01x
52-Week HighHighest price in past year$0.21$28.44$90.88$999.00$233.60
52-Week LowLowest price in past year$0.00$9.23$58.35$637.00$137.75
% of 52W HighCurrent price vs 52-week peak+3.3%+41.2%+99.6%+73.7%+78.6%
RSI (14)Momentum oscillator 0–10047.253.170.021.028.6
Avg Volume (50D)Average daily shares traded40K3.3M7.5M782K1.8M
Evenly matched — CVS and MCK each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — PTPI and CAH each lead in 1 of 2 comparable metrics.

Analyst consensus: PRGO as "Hold", CVS as "Buy", MCK as "Buy", CAH as "Buy". Consensus price targets imply 209.1% upside for PRGO (target: $36) vs 6.8% for CVS (target: $97). For income investors, PTPI offers the higher dividend yield at 100.00% vs MCK's 0.42%.

MetricPTPI logoPTPIPetros Pharmaceut…PRGO logoPRGOPerrigo Company p…CVS logoCVSCVS Health Corpor…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …
Analyst RatingConsensus buy/hold/sellHoldBuyBuyBuy
Price TargetConsensus 12-month target$36.20$96.75$994.86$253.38
# AnalystsCovering analysts36413133
Dividend YieldAnnual dividend ÷ price+100.0%+9.8%+3.0%+0.4%+1.1%
Dividend StreakConsecutive years of raises11001820
Dividend / ShareAnnual DPS$161.09$1.15$2.67$3.07$2.04
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%0.0%0.0%+1.8%
Evenly matched — PTPI and CAH each lead in 1 of 2 comparable metrics.
Key Takeaway

PRGO leads in 1 of 6 categories (Valuation Metrics). MCK leads in 1 (Profitability & Efficiency). 4 tied.

Best OverallPerrigo Company plc (PRGO)Leads 1 of 6 categories
Loading custom metrics...

PTPI vs PRGO vs CVS vs MCK vs CAH: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is PTPI or PRGO or CVS or MCK or CAH a better buy right now?

For growth investors, McKesson Corporation (MCK) is the stronger pick with 12.

4% revenue growth year-over-year, versus -12. 2% for Petros Pharmaceuticals, Inc. (PTPI). McKesson Corporation (MCK) offers the better valuation at 19. 2x trailing P/E (16. 7x forward), making it the more compelling value choice. Analysts rate CVS Health Corporation (CVS) a "Buy" — based on 41 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — PTPI or PRGO or CVS or MCK or CAH?

On trailing P/E, McKesson Corporation (MCK) is the cheapest at 19.

2x versus CVS Health Corporation at 65. 1x. On forward P/E, Perrigo Company plc is actually cheaper at 5. 5x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — PTPI or PRGO or CVS or MCK or CAH?

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +270.

4%, compared to -100. 0% for Petros Pharmaceuticals, Inc. (PTPI). Over 10 years, the gap is even starker: MCK returned +339. 0% versus PTPI's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — PTPI or PRGO or CVS or MCK or CAH?

By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at -0.

02β versus Petros Pharmaceuticals, Inc. 's 1. 45β — meaning PTPI is approximately -8948% more volatile than MCK relative to the S&P 500. On balance sheet safety, McKesson Corporation (MCK) carries a lower debt/equity ratio of 110% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.

05

Which is growing faster — PTPI or PRGO or CVS or MCK or CAH?

By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 12.

4% versus -12. 2% for Petros Pharmaceuticals, Inc. (PTPI). On earnings-per-share growth, the picture is similar: Cardinal Health, Inc. grew EPS 87. 0% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, MCK leads at 13. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — PTPI or PRGO or CVS or MCK or CAH?

McKesson Corporation (MCK) is the more profitable company, earning 1.

2% net margin versus -280. 1% for Petros Pharmaceuticals, Inc. — meaning it keeps 1. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRGO leads at 8. 1% versus -345. 8% for PTPI. At the gross margin level — before operating expenses — PTPI leads at 76. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is PTPI or PRGO or CVS or MCK or CAH more undervalued right now?

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

5x forward P/E versus 17. 1x for Cardinal Health, Inc. — 11. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 209. 1% to $36. 20.

08

Which pays a better dividend — PTPI or PRGO or CVS or MCK or CAH?

All stocks in this comparison pay dividends.

Petros Pharmaceuticals, Inc. (PTPI) offers the highest yield at 100. 0%, versus 0. 4% for McKesson Corporation (MCK).

09

Is PTPI or PRGO or CVS or MCK or CAH better for a retirement portfolio?

For long-horizon retirement investors, Cardinal Health, Inc.

(CAH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 01), 1. 1% yield, +158. 8% 10Y return). Both have compounded well over 10 years (CAH: +158. 8%, PTPI: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between PTPI and PRGO and CVS and MCK and CAH?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PTPI is a small-cap income-oriented stock; PRGO is a small-cap income-oriented stock; CVS is a mid-cap quality compounder stock; MCK is a mid-cap quality compounder stock; CAH is a mid-cap quality compounder stock. PTPI, PRGO, CVS, CAH pay a dividend while MCK does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

PTPI

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $2B
  • Gross Margin > 38%
  • Dividend Yield > 40.0%
Run This Screen
Stocks Like

PRGO

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 20%
  • Dividend Yield > 3.9%
Run This Screen
Stocks Like

CVS

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 1.1%
Run This Screen
Stocks Like

MCK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

CAH

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform PTPI and PRGO and CVS and MCK and CAH on the metrics below

Revenue Growth>
%
(PTPI: -100.0% · PRGO: -7.2%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.